Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jan;269(1):72-86.
doi: 10.1007/s00415-020-10320-9. Epub 2021 Jan 2.

Effects of intratympanic gentamicin and intratympanic glucocorticoids in Ménière's disease: a network meta-analysis

Weiming Hao  1   2 , Huiqian Yu  3   4 , Huawei Li  5   6   7   8
Affiliations

Effects of intratympanic gentamicin and intratympanic glucocorticoids in Ménière's disease: a network meta-analysis

Weiming Hao et al. J Neurol. 2022 Jan.

Abstract

Objective: Intratympanic therapies, usually including glucocorticoid and gentamicin, are becoming worldwide used in clinical practice of Ménière's disease today. However, clinical efficacy and safety of these two therapies are still in controversial.

Data sources: Electronic searches in PubMed, CENTRAL, Web of Science, EMBASE, CINAHL, ClinicalTrials.gov and the European Union Clinical Trials Register were conducted from inception until September 2020.

Review methods: The pre-specified protocol of this systematic review and meta-analysis has been registered and published in November 2018 (PROSPERO Identifier: CRD42018114389). All randomized controlled trials of intratympanic gentamicin or glucocorticoids for Ménière's disease, compared with each other or placebo, were considered for this review.

Results: Ten studies with 455 patients met the inclusion criteria. Pooled results indicated significant advantage of intratympanic gentamicin and glucocorticoids over placebo treatments in vertigo control (gentamicin vs placebo: risk rate, RR, 2.56; 95% CI 1.18-5.54; glucocorticoids vs placebo: RR, 3.02; 95% CI 1.36-6.73). There was no significant difference between gentamicin and glucocorticoids in vertigo control (gentamicin vs placebo: RR, 1.18; 95% CI 0.97-1.45). Intratympanic glucocorticoids showed better hearing protective results than gentamicin (change of pure tone audiometric, PTA, mean difference, MD, - 6.48 dB; 95% CI - 11.84 to - 1.13 dB; change of speech discrimination scale, SDS, MD 7.69%; 95% CI 0.83-14.55%).

Conclusions: Intratympanic gentamicin and glucocorticoids are two effective approaches to control vertigo symptoms for Ménière's disease. Glucocorticoids showed a potentially better hearing protective role over gentamicin.

Keywords: Intratympanic gentamicin; Intratympanic glucocorticoids; Ménière’s disease; Network meta-analysis.

PubMed Disclaimer

References

    1. Alexander TH, Harris JP (2010) Current epidemiology of Meniere’s syndrome. Otolaryngol Clin North Am 43(5):965–970 - PubMed
    1. Shojaku H, Watanabe Y, Fujisaka M, Tsubota M, Kobayashi K, Yasumura S, Mizukoshi K (2005) Epidemiologic characteristics of definite Meniere’s disease in Japan. A long-term survey of Toyama and Niigata prefectures. ORL J Otorhinolaryngol Relat Spec 67(5):305–309 - PubMed
    1. Ikeda M, Sando I (1984) Endolymphatic duct and sac in patients with Meniere’s disease. A temporal bone histopathological study. Ann Otol Rhinol Laryngol 93(6 Pt 1):540–546 - PubMed
    1. Sando I, Ikeda M (1984) The vestibular aqueduct in patients with Meniere’s disease. A temporal bone histopathological investigation. Acta Otolaryngol 97(5–6):558–570 - PubMed
    1. Zechner G, Altmann F (1969) Histological studies on the human endolymphatic duct and sac. Pract Otorhinolaryngol (Basel) 31(2):65–83

Publication types

LinkOut - more resources